 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Serious Liver and Metabolism Problems Associated with Use of the Anti-HIV Drug Stavudine
1 August 2000 | Volume 133 Issue 3 | Page 192
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases." It is in the 1 August 2000 issue of Annals of Internal Medicine (volume 133, pages 192-196). The authors are K.D. Miller, M. Cameron, L.V. Wood, M.C. Dalakas, and J.A. Kovacs.
What is the problem and what is known about it so far?
Fatty infiltration of the liver (hepatic steatosis) combined with high levels of a certain type of acid (lactic acidosis) is an uncommon but potentially fatal combination of complications that has been reported with use of the anti-HIV drugs didanosine and zidovudine. Stavudine, one of the most commonly used anti-HIV medicines, has rarely been associated with these complications.
Why did the researchers do this particular study?
To describe the medical history of four patients who developed hepatic steatosis and lactic acidosis while taking stavudine.
Who was studied?
Four patients with HIV infection who had been taking stavudine for 3 to 15 months in combination with other anti-HIV drugs.
How was the study done?
The authors reported the clinical findings and laboratory tests of the four patients and described the time course of the illness that developed in each patient.
What did the researchers find?
All of the patients developed lactic acidosis and abnormal blood levels of liver enzymes. Computed tomographic (CAT) scans showed fatty deposits in their livers. Two of the patients had elevated blood levels of muscle enzymes, and two also had inflammation of the pancreas. Small samples of liver tissue (liver biopsies) were obtained from two patients during their illness; these samples showed hepatic steatosis. Small pieces of muscle tissue (muscle biopsies) were also taken from two patients; these samples showed the same type of muscle damage that has been associated with use of didanosine and zidovudine in other studies. All four patients had long, complicated hospital stays, but they recovered after stavudine therapy was stopped. Once they had recovered, all patients began taking other anti-HIV drugs without a problem.
What were the limitations of the study?
This report describes only four patients who developed these complications while taking stavudine. The report suggests but does not prove that stavudine caused the hepatic steatosis and lactic acidosis. In addition, the report does not provide any information about how often stavudine might cause these complications.
What are the implications of the study?
Patients taking stavudine should be aware that these rare but serious complications can occur. Doctors should consider the possibility of these complications in patients who become ill while taking stavudine.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  P. J. Fall and H. M. Szerlip Lactic Acidosis: From Sour Milk to Septic Shock J Intensive Care Med, September 1, 2005; 20(5): 255 - 271. [Abstract] [PDF]
|
|
|
|
 |
|
 D. C. Rudorf and S. A. Krikorian Adverse Effects Associated With Antiretroviral Therapy and Potential Management Strategies Journal of Pharmacy Practice, August 1, 2005; 18(4): 258 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 H.-Y. Lai, J.-H. Chen, P.-P. Tsai, M.-W. Ho, and W.-C. Shen Hepatic Steatosis and Pancreatitis Associated with the Use of Stavudine in a Patient with HIV Infection Am. J. Roentgenol., December 1, 2004; 183(6): 1605 - 1607. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mora, I. Zamproni, S. Beccio, R. Bianchi, V. Giacomet, and A. Vigano Longitudinal Changes of Bone Mineral Density and Metabolism in Antiretroviral-Treated Human Immunodeficiency Virus-Infected Children J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 24 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Arenas-Pinto, A D Grant, S Edwards, and I V D Weller Lactic acidosis in HIV infected patients: a systematic review of published cases Sex. Transm. Inf., August 1, 2003; 79(4): 340 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Marceau, V. Sapin, C. Jacomet, S. Ughetto, L. Cormerais, C. Regagnon, B. Dastugue, H. Peigue-Lafeuille, J. Beytout, and H. Laurichesse Frequency, Risk Factors, and Outcome of Hyperlactatemia in HIV-positive Persons: Implications for the Management of Treated Patients Clin. Chem., July 1, 2003; 49(7): 1154 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Pakyz, Y. Newberry, and G. C. Townsend Human Immunodeficiency Virus Infection: A Focus on Women Journal of Pharmacy Practice, June 1, 2003; 16(3): 170 - 181. [Abstract] [PDF]
|
|
|
|
 |
|
 M Tolomeo, S Mancuso, M Todaro, G Stassi, M Catalano, S Arista, G Cannizzo, E Barbusca, and V Abbadessa Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy J. Clin. Pathol., February 1, 2003; 56(2): 147 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H K Thaker and M H Snow HIV viral suppression in the era of antiretroviral therapy Postgrad. Med. J., January 1, 2003; 79(927): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Vasseur, H. Kawanishi, N. Shah, and M. L. Anderson Type B lactic acidosis: a rare complication of antiretroviral therapy after cardiac surgery Ann. Thorac. Surg., October 1, 2002; 74(4): 1251 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 HIV in Women: An Update AIDS Clinical Care, October 1, 2002; 2002(1001): 1 - 1. [Full Text]
|
|
|
|
 |
|
 H. Masur Acquired Immunodeficiency Syndrome in the Intensive Care Unit: Will Human Immunodeficiency Virus-related Admissions Continue to Decline? Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 258 - 259. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Zell and S. Nielsen Clinical Correlates to Muscle Biopsy Findings in HIV Patients Experiencing Fatigue: A case series J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2002; 1(3): 90 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Birkus, M. J. M. Hitchcock, and T. Cihlar Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors Antimicrob. Agents Chemother., March 1, 2002; 46(3): 716 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
NRTI-Associated Mitochondrial Toxicity AIDS Clinical Care, May 1, 2001; 2001(501): 7 - 7. [Full Text]
|
|
|
|
|
|
T. J. Kanmaz and N. J. Lee Significant Toxicities Associated with Antiretroviral Therapy Journal of Pharmacy Practice, December 1, 2000; 13(6): 457 - 474. [Abstract] [PDF]
|
|
|
|
|
|
Hepatic Steatosis and Lactic Acidosis with d4T-Containing Regimens AIDS Clinical Care, October 1, 2000; 2000(1001): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Lactic Acidosis Associated with Stavudine Journal Watch (General), August 11, 2000; 2000(811): 3 - 3. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
